Feldene
In brief
- Feldene (piroxicam) is a prescription-only medicine (POM) in the UK.
- Feldene is used to treat pain, inflammation and rheumatic conditions such as osteoarthritis and rheumatoid arthritis; it is a non‑steroidal anti‑inflammatory drug (NSAID) of the oxicam class that works mainly by inhibiting cyclooxygenase enzymes and reducing prostaglandin synthesis.
- The usual adult dose is 20 mg once daily (maximum 20 mg/day); some patients respond to 10 mg daily and doses may be split into 2 × 10 mg to lessen gastrointestinal side effects.
- Administered orally as capsules, tablets or dispersible tablets; a topical gel is also available for local use.
- Analgesic effects typically begin within about 30–60 minutes after oral dosing; full anti‑inflammatory benefit may take several days of treatment.
- Duration of action is effectively once daily, with a long plasma half‑life (~50 hours) leading to sustained effect and potential for accumulation with prolonged use.
- Avoid alcohol while taking Feldene where possible, as alcohol increases the risk of gastrointestinal bleeding and may worsen dizziness or drowsiness.
- The most common side effects are gastrointestinal (nausea, dyspepsia, abdominal pain), and other frequent effects include headache, dizziness, skin rash and fluid retention.
- Would you like to try Feldene without a prescription?
Basic Feldene information
- INN (international nonproprietary name): Piroxicam
- Brand names available in the United Kingdom: Feldene (capsules 10 mg, 20 mg) and generic piroxicam products.
- ATC code: M01AC01
- Forms and dosages: Capsules/tablets 10 mg and 20 mg; dispersible 20 mg tablets; topical gel.
- Manufacturers in the United Kingdom: Pfizer (Feldene) and generic manufacturers such as Sandoz, Teva and Mylan.
- Registration status in the United Kingdom: Registered with the MHRA as a prescription medicine.
- OTC / Rx classification: Prescription‑Only Medicine (POM) in the UK.
Critical warnings and restrictions
High‑risk groups
Does this drug need special caution for older people, pregnancy or chronic illness?
Yes.
Piroxicam (Feldene) is prescription‑only in the UK and is an NSAID with an unusually long half‑life of about 50 hours, so adverse effects can be prolonged.
Absolute contraindications include known hypersensitivity to piroxicam or other NSAIDs, active peptic ulcer or gastrointestinal bleeding, severe heart failure, severe hepatic or renal impairment, use after coronary artery bypass graft (CABG), and pregnancy, especially the third trimester.
Elderly patients are at higher risk of gastrointestinal bleeding, renal impairment and cardiovascular events and should be prescribed the lowest effective dose with closer monitoring.
Concurrent use of anticoagulants, antiplatelets, systemic corticosteroids or a history of peptic ulcer disease increases risk and usually prompts gastroprotection with a proton pump inhibitor and regular review.
- Absolute contraindications: known hypersensitivity to piroxicam/NSAIDs; active peptic ulcer or GI bleeding; severe heart failure; severe hepatic or renal impairment; use after CABG; pregnancy (especially third trimester).
- Relative contraindications: history of mild to moderate renal or hepatic dysfunction; hypertension; prior ulcer disease; elderly age; current anticoagulant, antiplatelet or corticosteroid therapy.
Pre‑prescription checklist for clinicians and pharmacists before issuing or dispensing piroxicam:
- Confirm renal function (eGFR) and recent serum creatinine.
- Check blood pressure and cardiovascular history.
- Ask about prior peptic ulcer disease, GI bleeding or dyspepsia.
- Review all concurrent medications including anticoagulants, antiplatelets, SSRIs, lithium, methotrexate, ACE inhibitors/ARBs and diuretics.
- Document pregnancy status or plans for conception and breastfeeding.
- Assess patient age and frailty; consider starting at 10 mg if risk factors present.
Interaction with activities
Will piroxicam affect my ability to drive or work safely?
Drowsiness, dizziness and visual disturbance are known side effects.
Patients must be advised not to drive or operate heavy machinery until they know how piroxicam affects them.
Record safety counselling in patient notes and on the electronic prescription record so advice is traceable.
Q&A — “Can I drive after taking it in the UK?”
Q: Can I drive after taking Feldene?
A: Not as a routine rule if you feel normal; however, if you experience drowsiness, dizziness, blurred vision or slowed reactions you must not drive or operate heavy machinery.
UK driving law requires drivers to be fit to drive and free from side effects that may impair control, so any relevant symptoms should prompt immediate cessation of driving and contact with the prescriber.
If severe neurological symptoms occur, seek urgent medical attention.
Clinicians and pharmacists should counsel patients about the long half‑life of piroxicam — side effects may persist longer than with shorter‑acting NSAIDs — and note this on the patient record.
Report any serious suspected adverse reactions to the MHRA via the Yellow Card scheme.
Usage basics
INN, brand names available in the UK
What is the active ingredient and what are the UK brand options?
The International Nonproprietary Name is piroxicam.
It is marketed as Feldene in the UK, with generics available under the INN piroxicam.
Available dosage forms include 10 mg and 20 mg capsules or tablets and dispersible 20 mg tablets; a topical piroxicam gel is also available.
Legal classification
Is piroxicam a prescription or over‑the‑counter medicine in the UK?
Piroxicam is a Prescription‑Only Medicine (POM) in the UK and requires an NHS or private prescription to dispense.
When dispensed on the NHS, the Electronic Prescription Service (EPS) can send prescriptions to a nominated pharmacy for collection and counselling.
Pharmacists must provide the patient information leaflet and counselling at supply and record key safety advice in the patient record.
- INN: International Nonproprietary Name — piroxicam.
- POM: Prescription‑Only Medicine — requires an NHS or private prescription in the UK.
- SmPC: Summary of Product Characteristics — consult for detailed contraindications and monitoring.
- Common packaging and presentation: capsules/tablets 10 mg and 20 mg in blister packs or bottles.
- Dispersible 20 mg tablets and a topical gel are also available; availability varies by supplier.
Dosing guide
Standard regimens
How is piroxicam usually dosed for arthritis?
The typical adult dose for osteoarthritis and rheumatoid arthritis is 20 mg once daily, with a maximum of 20 mg per day.
Some patients obtain adequate symptom control at 10 mg once daily and prescribers often trial the lower dose in sensitive patients.
Because piroxicam has an approximate half‑life of 50 hours, it reaches steady state slowly and adverse effects can accumulate over time.
Use the lowest effective dose for the shortest period necessary and reassess regularly.
Treatment for chronic conditions should be reviewed every 2–3 months, with consideration of short courses where clinically appropriate.
| Indication | Typical dose | Maximum dose |
|---|---|---|
| Osteoarthritis | 20 mg once daily (10 mg may be tried) | 20 mg/day |
| Rheumatoid arthritis | 20 mg once daily (may split to 2 × 10 mg to reduce GI symptoms) | 20 mg/day |
Baseline tests to complete before initiating piroxicam:
- Blood pressure measurement.
- Renal function (eGFR, serum creatinine).
- Liver function tests.
- History of peptic ulcer or GI bleeding.
Adjustments for comorbidities
How should piroxicam be adapted for older adults and those with medical problems?
Elderly patients should receive the lowest effective dose and require more frequent monitoring for gastrointestinal bleeding, renal impairment and cardiovascular events.
In renal or hepatic impairment piroxicam should generally be avoided or used only with specialist advice and tight monitoring because elimination may be prolonged and toxicity heightened.
If co‑prescribing diuretics, ACE inhibitors or anticoagulants review the necessity of piroxicam and monitor renal function, electrolytes and coagulation parameters as indicated.
Q&A — “What if I miss a dose?”
Q: What should I do if I miss a dose of Feldene?
A: Take the missed dose as soon as you remember unless it is nearly time for your next dose.
Do not take a double dose to make up for a missed dose.
Because piroxicam accumulates owing to its long half‑life, consistent daily dosing is preferable; if you miss doses frequently contact your prescriber or pharmacist for advice.
Interaction chart
Food and drinks
Are there dietary issues while taking piroxicam?
Alcohol increases the risk of gastrointestinal bleeding when combined with NSAIDs and patients should be advised to minimise alcohol intake while taking piroxicam.
No specific food interactions are documented, but taking piroxicam with food may reduce GI upset.
Caffeine‑containing drinks such as coffee or tea have no direct pharmacokinetic interaction but stimulants can mask drowsiness; counsel accordingly.
- Dietary advice: take with food if you experience stomach upset.
- Alcohol limits: advise minimising alcohol while taking piroxicam due to raised GI bleed risk.
Common drug conflicts
Which medicines commonly interact with piroxicam and how should they be managed?
| Drug | Mechanism | Clinical action / monitoring |
|---|---|---|
| Warfarin / DOACs | Increased bleeding risk via platelet function inhibition and GI mucosal damage | Avoid combination where possible; if necessary monitor INR and signs of bleeding closely; consider alternative analgesia. |
| Antiplatelets (aspirin, clopidogrel) | Higher GI bleeding risk | Use gastroprotection and regular review; involve prescriber in risk/benefit decision. |
| SSRIs | Increased GI bleed risk | Monitor for GI symptoms; consider PPI if combined and risk factors present. |
| ACE inhibitors / ARBs / diuretics | Reduced renal perfusion and possible loss of antihypertensive effect | Monitor renal function and blood pressure; avoid in known renal impairment. |
| Corticosteroids | Increased GI ulceration risk | Consider gastroprotection and close monitoring. |
| Lithium, methotrexate | Reduced renal clearance leading to higher serum levels | Monitor drug levels and renal function; consider alternative therapy. |
Report suspected interactions and serious adverse reactions to the MHRA Yellow Card scheme.
Stepwise checklist for managing interactions in primary care:
- Review the patient’s full medication list and check for anticoagulants, antiplatelets, SSRIs, lithium, methotrexate and ACE inhibitors/diuretics.
- Assess baseline renal and liver function and BP.
- Decide on gastroprotection if bleeding risk is present.
- Document monitoring plan and review dates in the record.
Legal status and availability in the UK
In our online pharmacy, Feldene is available without a prescription, with discreet delivery to the United Kingdom in 9–21 days.
Mechanism and pharmacology
Simplified explanation
How does piroxicam work in plain language?
Piroxicam is a non‑steroidal anti‑inflammatory drug (NSAID) that reduces pain and inflammation by inhibiting cyclo‑oxygenase (COX) enzymes and lowering prostaglandin production.
This reduces joint pain and swelling but also decreases protective prostaglandins in the stomach, which raises the risk of ulcers and bleeding.
- NSAID: Non‑steroidal anti‑inflammatory drug.
- COX: Cyclo‑oxygenase enzyme that makes prostaglandins.
- Prostaglandin: Substances involved in inflammation and stomach protection.
- Half‑life: About 50 hours — long‑acting.
Clinical terms
Key pharmacology points for clinicians.
Piroxicam’s long half‑life (~50 hours) allows once‑daily dosing but increases the risk of accumulation and prolonged adverse events when compared with shorter‑acting NSAIDs.
| Parameter | Typical value |
|---|---|
| Half‑life | Approximately 50 hours |
| Onset | Within hours for analgesia; anti‑inflammatory effects may take days |
| Routes | Oral capsules/tablets; topical gel |
| Dosing forms | 10 mg, 20 mg tablets/capsules; dispersible 20 mg; topical gel |
- Monitoring schedule: baseline bloods (renal, liver), follow up at 4–12 weeks, then periodic reviews depending on risk and duration of therapy.
Indications and off‑label uses
MHRA‑approved uses
What is piroxicam licensed to treat in the UK?
Primary licensed indications are the symptomatic relief of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis, typically prescribed at 20 mg once daily with a maximum of 20 mg per day.
Topical gel formulations, where available, may be used for localised musculoskeletal pain to reduce systemic exposure; check product availability and local formulary guidance.
- Licensed indications: osteoarthritis, rheumatoid arthritis and ankylosing spondylitis.
- Formulation choices: oral systemic therapy (capsules/tablets) or topical gel where marketed.
Off‑label practices in NHS and private care
Are there other clinical situations where piroxicam is used?
Occasionally piroxicam is used off‑label for acute gout or acute post‑operative pain under clinician judgement, but these uses must be justified given tolerability concerns.
Off‑label prescribing requires documentation of indication, informed consent and a monitoring plan.
- Checklist for off‑label prescribing: document indication, discuss benefits and risks with the patient, obtain consent, and set a monitoring and review schedule.
Alternatives matrix
NHS prescribing alternatives
| Drug | Typical NHS dose | Half‑life | GI/cardiac risk | Topical option |
|---|---|---|---|---|
| Ibuprofen | 200–400 mg TDS (OTC doses) / up to 2400 mg/day Rx | Short | Lower at OTC doses; cardiac risk less clear | Yes (topical formulations available) |
| Diclofenac | 50 mg BD/TDS | Moderate | Similar GI risk; cardiac risk highlighted | Yes (topical gel) |
| Meloxicam | 7.5–15 mg once daily | Longer (once daily) | Possibly lower GI risk vs non‑selective NSAIDs | No common topical |
| Naproxen | 250–500 mg BD | Longer | GI risk present; lower cardiac signal in some studies | No common topical |
Quick reference: choose ibuprofen for short‑term, low‑dose analgesia; diclofenac for similar efficacy with topical options; meloxicam where once‑daily dosing and lower GI risk is preferred; naproxen for longer dosing intervals.
Pros and cons checklist
- Consider patient comorbidities: cardiac, renal and GI disease.
- Assess drug interaction potential with current medicines.
- Decide between topical versus systemic therapy to reduce systemic exposure where appropriate.
- Weigh monitoring burden and patient preference into the prescribing decision and document rationale and gastroprotection plan.
Common questions
Which questions do patients ask most often in UK consultations?
- Q: Can I take Feldene in pregnancy or breastfeeding?
- A: Piroxicam is contraindicated in pregnancy, especially in the third trimester; breastfeeding requires individual risk assessment—consult your prescriber.
- Q: Can I combine it with paracetamol?
- A: Yes, paracetamol may be used for additional pain relief, but always check the total analgesic burden and liver function if long‑term or heavy alcohol use.
- Q: How long until it works?
- A: Analgesia can begin within hours, but full anti‑inflammatory benefit may take several days; the long half‑life means steady effect builds slowly.
Red‑flag symptoms requiring urgent review:
- Black or tarry stools or vomiting blood.
- Severe abdominal pain.
- Chest pain, sudden breathlessness or severe leg swelling.
- Marked reduction in urine output or sudden confusion.
Registration and regulation
MHRA approval process
Is piroxicam regulated in the UK?
Piroxicam (Feldene) is registered as a prescription medicine with the MHRA and prescribers should consult the SmPC for current contraindications, interactions and monitoring.
Suspected adverse reactions should be reported to the MHRA via the Yellow Card scheme.
- Regulatory checklist: locate the SmPC, check batch recalls and report adverse events via Yellow Card.
NHS prescribing framework
What responsibilities do prescribers have?
Prescribers must follow NHS formularies and local guidance, document informed consent and monitoring plans, and ensure patients receive leaflets and counselling at dispensing.
High‑risk cases should involve specialist review and clear documentation of rationale for choosing piroxicam over alternatives.
- Audit points: indication documented, baseline tests completed, review date recorded, gastroprotection decision noted.
Storage and handling
UK household storage
How should patients store piroxicam at home?
Store at room temperature as directed on the pack.
Keep in the original packaging away from moisture and direct sunlight and avoid storing in bathrooms where humidity is high.
Do not freeze topical gels.
- Safe storage checklist: temperature control, keep out of reach of children, check expiry dates, return unused medicine to a pharmacy for safe disposal.
Guidance from NHS and pharmacists (transport and travel)
Advice for travel and transport of piroxicam.
Carry medication in original packaging with the prescription or a copy when travelling and store at room temperature.
When travelling abroad check local regulations for carrying prescription medicines.
| Do | Don’t |
|---|---|
| Keep in original box with leaflet and prescription | Store in a car glovebox in hot weather |
| Use pharmacy return schemes for disposal | Dispose in household bin or sink |
Guidelines for proper use
UK pharmacist counselling style
What should pharmacists say at the point of supply?
Confirm the indication and dose (10 mg or 20 mg), warn about signs of GI bleeding and drowsiness, advise no alcohol and review concurrent medicines.
Explain the monitoring plan for blood pressure, renal function and liver tests and offer written information.
- Counselling checklist: confirm allergies, confirm pregnancy status, explain dose and duration, advise on driving and alcohol, provide leaflet and record EPS nomination.
Short script for common queries: “This medicine is piroxicam (Feldene). Take once daily as prescribed. If you notice black stools, severe stomach pain, breathlessness or a big change in urine or swelling, stop the medicine and seek urgent review.”
NHS patient safety advice
Follow‑up and escalation guidance for chronic users.
Recommend baseline blood tests before starting and a review after 4–12 weeks, then every 2–3 months for chronic therapy as clinically indicated.
Start a proton pump inhibitor for gastroprotection in patients with GI risk factors and arrange prompt review for red flags such as severe abdominal pain, black stools, chest pain or sudden fluid retention.
- Follow‑up timeline: baseline, 4–12 weeks, 6 months, then annually or as needed.
- Decision flow: continue at lowest effective dose with monitoring; reduce or stop if adverse events occur; refer to specialist for significant renal, hepatic or cardiac issues.
Encourage patients to report suspected adverse reactions with the MHRA Yellow Card scheme.
Delivery across the United Kingdom
| City | Region | Delivery Time |
|---|---|---|
| London | Greater London | 9–21 days |
| Birmingham | West Midlands | 9–21 days |
| Manchester | Greater Manchester | 9–21 days |
| Glasgow | Scotland | 9–21 days |
| Liverpool | Merseyside | 9–21 days |
| Leeds | West Yorkshire | 9–21 days |
| Edinburgh | Scotland | 9–21 days |
| Bristol | South West England | 9–21 days |
| Cardiff | Wales | 9–21 days |
| Belfast | Northern Ireland | 9–21 days |
| Newcastle | Tyne and Wear | 9–21 days |
| Sheffield | South Yorkshire | 9–21 days |
| Nottingham | Nottinghamshire | 9–21 days |
| Leicester | Leicestershire | 9–21 days |
| Coventry | West Midlands | 9–21 days |